Katherine C. Fuh, M.D., Ph.D.

Assistant Professor
Obstetrics and Gynecology
Gynecologic Oncology

Molecular Cell Biology Program

  • 314-362-8155

  • 314-747-1318

  • 8064

  • BJCIH 10th floor, Lab 10124

  • kfuh@wudosis.wustl.edu

  • ovarian cancer, receptor tyrosine kinase signaling, metastasis, EMT, tumor microenvironment

  • Identifying pathways involved in metastasis in the context of incorporating the tumor microenvironment of ovarian cancer

Research Abstract:

My current and future projects focus on identifying pathways involved in metastasis in the context of incorporating the tumor microenvironment of ovarian cancer. The stromal cells in the ovarian cancer microenvironment are cultured from omentum of patients taken from the operating room for our cell-based assays. For our in vivo models, we use syngeneic models of metastasis. Current project include:

1. Role of DDR2 in metastatic ovarian cancer.
2. Role of AXL in uterine serous cancer.
3. Reversal of chemoresistant ovarian and uterine cancer by genetic and therapeutic inactivation of AXL.
4. Characterizing targets identified from a functional genomic screen of metastatic ovarian cancer.
5. Identifying genetic alterations of ovarian cancer metastasis.
6. Stromal contribution of DDR2 in metastatic ovarian cancer.
7. Identifying pathways altered in chemoresistant tumors after neoadjuvant chemotherapy

Selected Publications:

Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK. (2015). Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol, 139(3):413-418.

Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, Chen LM, Chan JK. (2015). Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol, 136(3):491-7.

Rankin ER*, Fuh KC,* Castellini L, Viswanathan K., Finger E, Diep A, LaGory E, Lindgren D, Axelson H, Miao Y, Kariolis M, Krieg A, Giaccia A. (2014) Direct regulation of Gas6/AXL signaling by HIF. Proc Natl Acad Sci, 111(37): 13373-8. PMID: 25187556/PMC: 4169907

Chan J, Fuh K, Shin J, Cheung M, Powell B, Chen LM, Kapp D, Osann K. (2008) The treatment and outcomes of early-stage epithelial ovarian cancer – Have we made any progress? British Journal of Cancer, 98(7): 1191-6. PMID: 18349835/PMC: 2359639

Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ. (2010) AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Research, 70(19): 7570-9. PMID: 20858715/PMC: 3408227

*Denotes co-first author

Last Updated: 12/10/2015 5:13:34 PM

Back To Top

Follow us: